Corresponding to these earlier PCLS models of slowly progressive pulmonary diseases (e.g. interstitial lung diseases), our data might contribute to the development of further subacute or even CRD ex-vivo disease models and new therapeutic substances for these, particularly including slowly metabolized therapeutics.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}